Rezultati - Srđan Verstovšek

Refine Results
  1. 1
    Ruxolitinib for the treatment of myelofibrosis: its clinical potential

    Ruxolitinib for the treatment of myelofibrosis: its clinical potential od Srdan Verstovsek, Alen Ostojić, Vrhovac, Srdan Verstovsek

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis

    Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis od Srđan Verstovšek

    Izdano 2013
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Advanced systemic mastocytosis: the impact of <scp>KIT</scp> mutations in diagnosis, treatment, and progression

    Advanced systemic mastocytosis: the impact of <scp>KIT</scp> mutations in diagnosis, treatment, and progression od Srđan Verstovšek

    Izdano 2012
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Therapeutic potential of JAK2 inhibitors

    Therapeutic potential of JAK2 inhibitors od Srđan Verstovšek

    Izdano 2009
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    JAK2 inhibitors for myeloproliferative neoplasms: what is next?

    JAK2 inhibitors for myeloproliferative neoplasms: what is next? od Prithviraj Bose, Srđan Verstovšek

    Izdano 2017
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives

    JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives od Prithviraj Bose, Srđan Verstovšek

    Izdano 2020
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Clinical development and management of adverse events associated with FGFR inhibitors

    Clinical development and management of adverse events associated with FGFR inhibitors od Vivek Subbiah, Srđan Verstovšek

    Izdano 2023
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms

    Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms od Fabio P S Santos, Srđan Verstovšek

    Izdano 2012
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Efficacy of ruxolitinib for myelofibrosis

    Efficacy of ruxolitinib for myelofibrosis od Fabio P S Santos, Srđan Verstovšek

    Izdano 2014
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

    Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance od Alfonso Quintás‐Cardama, Srđan Verstovšek

    Izdano 2013
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

    Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib od Jeffrey C. Bryan, Srđan Verstovšek

    Izdano 2016
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Ruxolitinib: A New JAK1/2 Inhibitor That Offers Promising Options for Treatment of Myelofibrosis

    Ruxolitinib: A New JAK1/2 Inhibitor That Offers Promising Options for Treatment of Myelofibrosis od Alen Ostojić, Radovan Vrḫovac, Srđan Verstovšek

    Izdano 2011
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review

    The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review od Devendra Kc, Lorenzo Falchi, Srđan Verstovšek

    Izdano 2017
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Givinostat: an emerging treatment for polycythemia vera

    Givinostat: an emerging treatment for polycythemia vera od Helen T. Chifotides, Prithviraj Bose, Srđan Verstovšek

    Izdano 2020
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Momelotinib: an emerging treatment for myelofibrosis patients with anemia

    Momelotinib: an emerging treatment for myelofibrosis patients with anemia od Helen T. Chifotides, Prithviraj Bose, Srđan Verstovšek

    Izdano 2022
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments

    Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments od Helen T. Chifotides, Srđan Verstovšek, Prithviraj Bose

    Izdano 2023
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    JAK2 Inhibitors: Are They the Solution?

    JAK2 Inhibitors: Are They the Solution? od Fábio Pires de Souza Santos, Srđan Verstovšek

    Izdano 2011
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

    Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib od John Mascarenhas, Tariq I. Mughal, Srđan Verstovšek

    Izdano 2012
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignancies

    Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignancies od Amit Panwalkar, Srđan Verstovšek, Francis J. Giles

    Izdano 2004
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    JAK2 inhibitors: What's the true therapeutic potential?

    JAK2 inhibitors: What's the true therapeutic potential? od Fábio Pires de Souza Santos, Srđan Verstovšek

    Izdano 2010
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: